[
Aas AM, Ohrvik J, Malmberg K, Ryden L, Birkeland KI. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study. Diabetes Obes Metab 11, 323–329, 2009.
]Search in Google Scholar
[
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 44, S111–124, 2021.
]Search in Google Scholar
[
Cho KY, Nakamura A, Oba-Yamamoto C, Tsuchida K, Yanagiya S, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Switching to once-daily insulin degludec/insulin aspart from basal insulin improves postprandial glycemia in patients with type 2 diabetes mellitus: randomized controlled trial. Diabetes Metab J 44, 532–541, 2020.
]Search in Google Scholar
[
Christiansen JS, Home P, Kumar A. IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. Expert Rev Endocrinol Metab 11, 103–111, 2016.
]Search in Google Scholar
[
Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther 10, 273–277, 2008.
]Search in Google Scholar
[
DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 11, 567–573, 1988.
]Search in Google Scholar
[
Edina BC, Tandaju JR, Wiyono L. Efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in type 2 diabetes: systematic review and meta-analysis. Cureus 14, e25612, 2022.
]Search in Google Scholar
[
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach - update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149, 2015.
]Search in Google Scholar
[
Kalra S. Insulin degludec aspart: the first co-formulation of insulin analogues. Diabetes Ther 5, 65–72, 2014.
]Search in Google Scholar
[
Kisioglu SV, Demir AS, Tufekci D, Emur Gunay Y, Coskun H, Ucuncu O, Nuhoglu I, Kocak M, Karakullukcu S, Ersoz HO. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience. Int J Clin Pract 75, e14377, 2021.
]Search in Google Scholar
[
Kumar S, Jang HC, Demirag NG, Skjoth TV, Endahl L, Bode B. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with type 2 diabetes: a randomized, treat-to-target study. Diabet Med 34, 180–188, 2017.
]Search in Google Scholar
[
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-ERPI. A new equation to estimate glomerular filtration rate. Ann Inter Med 150, 604–612, 2009.
]Search in Google Scholar
[
Luo Q, Zhou L, Zhou N, Hu M. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes. Front Public Health 10, 1016937, 2022.
]Search in Google Scholar
[
Magliano DJ, Boyko EJ. IDF Diabetes Atlas 10th Edition Scientific Committee: Diabetes Atlas. In., 10th ed. Brussels, Belgium, International Diabetes Federation, 2021.
]Search in Google Scholar
[
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8, 728–742, 2012.
]Search in Google Scholar
[
Mohamed M, Lim SC, Mumtaz M, Uppal S, Mukherjee D, Kassim MSM, Sreedharan S, Doraiswamy AM, Chong KM, Tat LY, Nordin SB, Giek JLH, Hussein Z, Kadir KA, Lau BK, Chan SP. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes in Malaysia: results from a prospective, non-interventional real-world study. J ASEAN Fed Endocr Soc 38, 37–44, 2023.
]Search in Google Scholar
[
Onishi Y, Ono Y, Rabol R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 15, 826–832, 2013.
]Search in Google Scholar
[
Paul SK, Shaw JE, Montvida O, Klein K. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes. Diabetes Obes Metab 18, 1244–1252, 2016.
]Search in Google Scholar
[
Philis-Tsimikas A, Astamirova K, Gupta Y, Haggag A, Roula D, Bak BA, Fita EG, Nielsen AM, Demir T. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract 147, 157–165, 2019.
]Search in Google Scholar
[
Ryzodeg. European Medicines Agency: European public assessment report (EPAR) - Product information, available at https://www.ema.europa.eu/en/medicines/human/EPAR/ryzodeg, last update on 04/03/2025.
]Search in Google Scholar
[
Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J, TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 28, 169–180, 2013.
]Search in Google Scholar
[
Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26, 590–596, 2003.
]Search in Google Scholar
[
Zachariah S, Sheldon B, Shojaee-Moradie F, Jackson NC, Backhouse K, Johnsen S, Jones RH, Umpleby AM, Russell-Jones DL. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care 34, 1487–1491, 2011.
]Search in Google Scholar
